Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GCP Inspections: Corrective Measures For Adverse Findings Should Be Tested, US FDA Says

Executive Summary

Sponsors, CROs and study investigators who receive an FDA Form 483 following a good clinical practice inspection should acknowledge the agency’s observations, explain the corrective actions planned, and how efficacy of those measures will be assessed, CDER officials say.

You may also be interested in...



Good Clinical Practice Inspections Take On Narrower Focus During Pandemic, US FDA Says

Technological and logistical challenges have forced agency staff to triage document and interview requests to focus on the most important issues when conducting remote regulatory assessments and in-person inspections, an FDA official told a conference of international regulators.

Foreign Data: Sintilimab’s Development Shows What Not To Do When Pursuing US Approval

The FDA’s concerns about conduct of ORIENT-11 trial include adequacy of informed consent, uncertainty about confidence in data generated in China, and failure of development partners Innovent and Eli Lilly to consult the US regulator about the study’s design.

How The US FDA’s Inspectional Approach Is Shifting For The Post-Pandemic Era

Agency hints of a “hybrid” future of in-person inspections supplemented by alternative tools like remote interactive evaluations.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS145779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel